Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis
Objectives Ki-67, a marker of cellular proliferation, is associated with prognosis across a wide range of tumours, including gastroenteropancreatic neuroendocrine neoplasms (NENs), lymphoma, urothelial tumours and breast carcinomas. Its omission from the classification system of pulmonary NENs is co...
| প্রধান লেখক: | , , , , , , , , , |
|---|---|
| বিন্যাস: | প্রবন্ধ |
| ভাষা: | English |
| প্রকাশিত: |
BMJ Publishing Group
2022-03-01
|
| মালা: | BMJ Open |
| অনলাইন ব্যবহার করুন: | https://bmjopen.bmj.com/content/12/3/e041961.full |
| _version_ | 1827060975867527168 |
|---|---|
| author | Salma Naheed Chloe Holden Lulu Tanno Eleanor Jaynes Judith Cave Giuseppe Pelosi Neil W Pearce Bryan Green Linda Pattini Christian H. Ottensmeier |
| author_facet | Salma Naheed Chloe Holden Lulu Tanno Eleanor Jaynes Judith Cave Giuseppe Pelosi Neil W Pearce Bryan Green Linda Pattini Christian H. Ottensmeier |
| author_sort | Salma Naheed |
| collection | DOAJ |
| description | Objectives Ki-67, a marker of cellular proliferation, is associated with prognosis across a wide range of tumours, including gastroenteropancreatic neuroendocrine neoplasms (NENs), lymphoma, urothelial tumours and breast carcinomas. Its omission from the classification system of pulmonary NENs is controversial. This systematic review sought to assess whether Ki-67 is a prognostic biomarker in lung NENs and, if feasible, proceed to a meta-analysis.Research design and methods Medline (Ovid), Embase, Scopus and the Cochrane library were searched for studies published prior to 28 February 2019 and investigating the role of Ki-67 in lung NENs. Eligible studies were those that included more than 20 patients and provided details of survival outcomes, namely, HRs with CIs according to Ki-67 percentage. Studies not available as a full text or without an English manuscript were excluded. This study was prospectively registered with PROSPERO.Results Of 11 814 records identified, seven studies met the inclusion criteria. These retrospective studies provided data for 1268 patients (693 TC, 281 AC, 94 large cell neuroendocrine carcinomas and 190 small cell lung carcinomas) and a meta-analysis was carried out to estimate a pooled effect. Random effects analyses demonstrated an association between a high Ki-67 index and poorer overall survival (HR of 2.02, 95% CI 1.16 to 3.52) and recurrence-free survival (HR 1.42; 95% CI 1.01 to 2.00).Conclusion This meta-analysis provides evidence that high Ki-67 labelling indices are associated with poor clinical outcomes for patients diagnosed with pulmonary NENs. This study is subject to inherent limitations, but it does provide valuable insights regarding the use of the biomarker Ki-67, in a rare tumour.Prospero registration number CRD42018093389. |
| first_indexed | 2025-02-18T19:21:06Z |
| format | Article |
| id | doaj.art-5482897f0b694ef68b9a885ffd792043 |
| institution | Directory Open Access Journal |
| issn | 2044-6055 |
| language | English |
| last_indexed | 2025-02-18T19:21:06Z |
| publishDate | 2022-03-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | BMJ Open |
| spelling | doaj.art-5482897f0b694ef68b9a885ffd7920432024-10-19T16:25:12ZengBMJ Publishing GroupBMJ Open2044-60552022-03-0112310.1136/bmjopen-2020-041961Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysisSalma Naheed0Chloe Holden1Lulu Tanno2Eleanor Jaynes3Judith Cave4Giuseppe Pelosi5Neil W Pearce6Bryan Green7Linda Pattini8Christian H. Ottensmeier9medical student2 Department of Oncology, Wessex NET Group ENETS Centre of Excellence, University Hospital Southampton NHS Foundation Trust, Southampton, UK1 Cancer Sciences Unit, NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton, University of Southampton Faculty of Medicine, Southampton, UKUniversity Hospital Southampton NHS Foundation Trust, Southampton, UKDepartment of Oncology, Wessex NET group ENETS Centre of Excellence, University Hospital Southampton NHS Foundation Trust, Southampton, UK4 Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy3 University Hospital Southampton NHS Foundation Trust, Southampton, UKDepartment of Pathology, Southampton University Hospitals NHS Trust, Southampton, UKDepartment of Electronics, Information and Bioengineering, Polytechnic of Milan, Milano, Lombardia, ItalyCancer Sciences Unit, NIHR and CRUK Experimental Cancer Medicine Center and NIHR Biomedical Research Center Southampton, University of Southampton, Southampton, UKObjectives Ki-67, a marker of cellular proliferation, is associated with prognosis across a wide range of tumours, including gastroenteropancreatic neuroendocrine neoplasms (NENs), lymphoma, urothelial tumours and breast carcinomas. Its omission from the classification system of pulmonary NENs is controversial. This systematic review sought to assess whether Ki-67 is a prognostic biomarker in lung NENs and, if feasible, proceed to a meta-analysis.Research design and methods Medline (Ovid), Embase, Scopus and the Cochrane library were searched for studies published prior to 28 February 2019 and investigating the role of Ki-67 in lung NENs. Eligible studies were those that included more than 20 patients and provided details of survival outcomes, namely, HRs with CIs according to Ki-67 percentage. Studies not available as a full text or without an English manuscript were excluded. This study was prospectively registered with PROSPERO.Results Of 11 814 records identified, seven studies met the inclusion criteria. These retrospective studies provided data for 1268 patients (693 TC, 281 AC, 94 large cell neuroendocrine carcinomas and 190 small cell lung carcinomas) and a meta-analysis was carried out to estimate a pooled effect. Random effects analyses demonstrated an association between a high Ki-67 index and poorer overall survival (HR of 2.02, 95% CI 1.16 to 3.52) and recurrence-free survival (HR 1.42; 95% CI 1.01 to 2.00).Conclusion This meta-analysis provides evidence that high Ki-67 labelling indices are associated with poor clinical outcomes for patients diagnosed with pulmonary NENs. This study is subject to inherent limitations, but it does provide valuable insights regarding the use of the biomarker Ki-67, in a rare tumour.Prospero registration number CRD42018093389.https://bmjopen.bmj.com/content/12/3/e041961.full |
| spellingShingle | Salma Naheed Chloe Holden Lulu Tanno Eleanor Jaynes Judith Cave Giuseppe Pelosi Neil W Pearce Bryan Green Linda Pattini Christian H. Ottensmeier Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis BMJ Open |
| title | Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis |
| title_full | Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis |
| title_fullStr | Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis |
| title_full_unstemmed | Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis |
| title_short | Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis |
| title_sort | utility of ki 67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms a systematic review and meta analysis |
| url | https://bmjopen.bmj.com/content/12/3/e041961.full |
| work_keys_str_mv | AT salmanaheed utilityofki67asaprognosticbiomarkerinpulmonaryneuroendocrineneoplasmsasystematicreviewandmetaanalysis AT chloeholden utilityofki67asaprognosticbiomarkerinpulmonaryneuroendocrineneoplasmsasystematicreviewandmetaanalysis AT lulutanno utilityofki67asaprognosticbiomarkerinpulmonaryneuroendocrineneoplasmsasystematicreviewandmetaanalysis AT eleanorjaynes utilityofki67asaprognosticbiomarkerinpulmonaryneuroendocrineneoplasmsasystematicreviewandmetaanalysis AT judithcave utilityofki67asaprognosticbiomarkerinpulmonaryneuroendocrineneoplasmsasystematicreviewandmetaanalysis AT giuseppepelosi utilityofki67asaprognosticbiomarkerinpulmonaryneuroendocrineneoplasmsasystematicreviewandmetaanalysis AT neilwpearce utilityofki67asaprognosticbiomarkerinpulmonaryneuroendocrineneoplasmsasystematicreviewandmetaanalysis AT bryangreen utilityofki67asaprognosticbiomarkerinpulmonaryneuroendocrineneoplasmsasystematicreviewandmetaanalysis AT lindapattini utilityofki67asaprognosticbiomarkerinpulmonaryneuroendocrineneoplasmsasystematicreviewandmetaanalysis AT christianhottensmeier utilityofki67asaprognosticbiomarkerinpulmonaryneuroendocrineneoplasmsasystematicreviewandmetaanalysis |